Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ADMA Biologics (ADMA)

ADMA Biologics Q2 revenue rises 2% to $124.4 million; net income up 11%

Positive Impact 3 of 5 earnings Written later

ADMA Biologics reported second quarter 2026 revenue of $124.4 million, up 2% from a year earlier, and GAAP net income of $37.8 million, up 11%. The company reiterated its FY2026 guidance, including total revenue of $530 million to $560 million, and said it repurchased approximately 7.1 million shares in the quarter.

Key points

  • Q2 total revenue $124.4 million vs. $122.0 million; ASCENIV revenue $102.9 million, up 24%; BIVIGAM revenue $19.4 million, down 49%
  • GAAP net income $37.8 million vs. $34.2 million; GAAP basic EPS $0.17 vs. $0.14; effective tax rate 24.7% vs. 14.7%
  • FY2026 guidance reiterated: total revenue $530 million to $560 million, Adjusted Net Income $170 million to $200 million, Adjusted EBITDA $265 million to $300 million
  • Repurchased approximately 7.1 million shares in Q2; company is on track for a $200 million or more 2026 share repurchase target

The filing

CompanyADMA Biologics (ADMA)
Form8-K, current report
Filed with the SECAug 5, 2026, 4:10 PM ET
Accession number0001140361-26-031423

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:49 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.